Investigating the effects of hormone therapy on HIV prevention in transgender individuals
Official title: CHIPP-PrEP: Cabotegravir-Hormone Interrogation of Pharmacokinetics/Pharmacodynamics for HIV Prevention in Cisgender and Transgender Persons
Funded at Johns Hopkins University · NIH-11002040 · Data updated 2026-11-12
This study is looking at how estrogen hormone therapy affects the way the HIV prevention pill cabotegravir works in transgender women and gender diverse people, so we can make sure they can safely use this medication while on hormone therapy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $616,760 |
| NIH project number | 1R01AI186440-01 |
| Project ID | NIH-11002040 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include transgender women and gender diverse persons assigned male at birth who are currently receiving or considering estrogen-based hormone therapy.
✕Less likely to help
Patients who are not transgender or gender diverse and do not use hormone therapy may not benefit from this research.
What this research studies
This research focuses on understanding how estrogen-based gender affirming hormone therapy (GAHT) affects the pharmacokinetics and pharmacodynamics of cabotegravir, a medication used for HIV prevention, in transgender women and gender diverse individuals assigned male at birth. The study aims to improve healthcare for these populations by examining the interaction between GAHT and long-acting cabotegravir for pre-exposure prophylaxis (PrEP). By characterizing these relationships, the research seeks to ensure that transgender individuals can safely and effectively use PrEP while undergoing hormone therapy. Participants will be monitored for drug concentrations and other pharmacological parameters to assess the effectiveness of this preventive treatment.
Why it matters
Potential benefit: If successful, this research could enhance HIV prevention strategies for transgender individuals, leading to better health outcomes and quality of life.
How similar studies have gone: Previous studies have shown promising results in HIV prevention using cabotegravir, particularly in populations similar to those targeted in this research, indicating a potential for success.
Where this research is happening
-
Johns Hopkins University
Baltimore, United States Active
Researchers
- Principal investigator: Marzinke, Mark a — Johns Hopkins University
- Study coordinator: Marzinke, Mark a
Related research
Other NIH-funded projects on the same topics.
-
CAB-LA and Hormones: How Biology Affects HIV Prevention Medicine
A Johns Hopkins study will look at how natural and added hormones might change how a long-acting HIV prevention drug works in the body.
-
How hormones affect long‑acting cabotegravir for HIV prevention
This project looks at how natural and taken hormones change how the long‑acting HIV prevention injection cabotegravir behaves in the body for people at risk of HIV.
-
Harnessing male peer networks to boost HIV testing and PrEP use
A large clinical trial in South Africa tests whether giving HIV self-test kits through male peer networks, with phone support, increases PrEP uptake among men.
-
Harnessing men's peer networks to boost HIV self-testing and PrEP use
A large project in South Africa tests whether giving HIV self-test kits through men’s social networks, with phone support, can lead to more men starting PrEP and using HIV testing.
-
TB PrEP: Bringing HIV prevention to households affected by TB in Uganda
Aims to help people in households with TB in Uganda access HIV PrEP as part of a combined prevention approach.
-
How choosing PrEP products could improve HIV protection for young women in Kenya
This project looks at which HIV-prevention options young Kenyan women prefer and how choosing a product affects how well they stay protected.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.